3.550EUR-5.08%Mkt Cap: 51.27M EURP/E: —Last update: 2026-06-01
THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap51.27M EUR
Enterprise Value46.72M EUR
Revenue (TTM)806.04K EUR
Gross Profit-2.34M EUR
Net Income (TTM)-3.00M EUR
Revenue/Share0.0580 EUR
Last Price3.550 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees—
CountryFR
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.03
PEG—
EV/EBITDA-11.86
EV/Revenue57.96
P/S67.01
P/B17.81
EPS (TTM)-0.22
EPS (Forward)-1.84
52W Range
0.742064% of range5.100
52W High5.100 EUR
52W Low0.7420 EUR
Profitability
Gross Margin-177.00%
Oper. Margin-144876610.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-103.45%
ROA-28.46%
Growth
Revenue Growth-100.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-821.60K EUR
CapEx (TTM)257.23K EUR
FCF Margin-364.26%
FCF Yield-5.73%
Net Debt-4.88M EUR
Net Debt/EBITDA1.24
Balance Sheet
Debt/Equity0.99
Current Ratio2.35
Quick Ratio2.32
Book Value/Sh0.2100 EUR
Cash/Share0.5630 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)5.800 EUR
Target Range5.800 EUR – 5.800 EUR
# Analysts1
Ownership
Shares Out.14.44M
Float13.13M
Insiders10.79%
Institutions7.78%
Technical
SMA 503.300 (+7.6%)
SMA 2002.632 (+34.9%)
Beta1.50
S&P 52W Chg27.94%
Avg Vol (30d)86.79K
Avg Vol (10d)119.05K
Technical Indicators
RSI (14)65.0
MACD0.0887
MACD Signal0.0623
MACD Hist.+0.0264
BB Upper3.725 EUR
BB Middle3.467 EUR
BB Lower3.209 EUR
BB Width14.87%
ATR (14)0.1963 EUR
Vol Ratio (20d)1.02x